The Applicability of Positive SARS-CoV-2 Rapid Antigen Test RNA for Whole Virus Sequencing and Variant Detection in Order to Preserve Genomic Surveillance

Aiden Mercer^*
*Correspondence: Aiden Mercer, Department of Molecular and Genetic Science, University of Tsukuba, Tsukuba, Ibaraki, Japan, Email:

Keywords

SARS-CoV-2 • Rapid antigen test • Genomic surveillance • Whole virus

Introduction

The emergence of diverse SARS-CoV-2 variants presents an ongoing challenge in managing the COVID-19 pandemic. As efforts intensify to track and understand these variants, the role of rapid antigen tests in genomic surveillance gains prominence beyond their conventional diagnostic application. Rapid antigen tests, known for their swift and reliable detection of viral antigens, provide an alternative method for detecting the presence of SARS-CoV-2. However, recent studies have revealed the potential to extract viral RNA from positive rapid antigen test samples. This revelation opens new doors in utilizing these tests for whole virus sequencing and variant detection. Rapid antigen tests, designed to identify specific viral proteins, initially seemed ill-suited for genomic sequencing. However, advancements in RNA extraction techniques have facilitated the extraction and sequencing of SARS-CoV-2 RNA from these tests' positive samples. Innovative methodologies leveraging Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) amplification enable the retrieval of viral genetic material for sequencing [1].

Literature Review

While the prospect of leveraging rapid antigen tests for genomic surveillance is promising, several challenges persist. The amount and quality of RNA obtained from these tests might vary, potentially affecting the accuracy and completeness of sequencing. Moreover, the sensitivity of these tests, designed primarily for antigen detection, might not consistently yield adequate RNA quantities for comprehensive genomic analysis. The integration of rapid antigen test RNA sequencing into existing genomic surveillance frameworks offers multifaceted benefits. It enables swift identification and tracking of emerging variants, facilitating real-time monitoring of viral evolution. This real-time data is instrumental in informing public health responses, aiding vaccine development, and optimizing control measures. For the effective integration of rapid antigen test RNA sequencing into genomic surveillance, standardization and validation protocols are imperative. Establishing standardized RNA extraction methods and ensuring the compatibility of sequencing platforms with limited RNA samples are critical steps. Additionally, continuous validation against gold-standard sequencing methodologies is essential to uphold accuracy and reliability. The convergence of rapid antigen tests and genomic sequencing represents a bridge between the diagnostic and genomic surveillance realms. While rapid antigen tests excel in their speed and simplicity for identifying active infections, their integration with RNA sequencing technologies harnesses valuable genetic information crucial for understanding viral evolution [2].

Discussion

Genomic surveillance remains pivotal in guiding public health responses. The ability to swiftly detect and characterize emerging variants through rapid antigen test RNA sequencing strengthens the adaptability of response strategies. Early identification of concerning variants facilitates targeted interventions, such as enhanced testing, contact tracing, and tailored vaccine development, mitigating potential outbreaks. As these methodologies evolve, ethical considerations regarding informed consent, data privacy, and equitable access to emerging technologies are paramount. Balancing the urgency of pandemic response with ethical frameworks ensures the responsible implementation and utilization of these innovative approaches. Global collaboration is indispensable in standardizing protocols and sharing insights regarding the integration of rapid antigen tests into genomic surveillance. Collaborative research initiatives, along with robust international data-sharing mechanisms, foster a collective approach in navigating the intricacies of variant tracking and addressing emerging challenges [3].

Future research and technological advancements hold the potential to optimize RNA extraction techniques from rapid antigen tests, enhancing the reliability and scalability of sequencing efforts. Furthermore, investments in infrastructure, training, and resource allocation can fortify public health systems for sustainable genomic surveillance. The incorporation of positive SARS-CoV-2 rapid antigen test RNA sequencing into genomic surveillance marks a significant stride toward an agile and adaptive approach to pandemic management. As viral variants continue to emerge and evolve, the synergy between diagnostics and genomic analysis becomes pivotal in bolstering our defenses against the virus [4].

Educating healthcare professionals, researchers, and the public about the expanded utility of rapid antigen tests fosters awareness and encourages their effective utilization. Clear communication regarding the advantages, limitations, and implications of this novel application is essential to garner support and trust. The landscape of viral evolution is dynamic, necessitating continuous innovation and adaptation in surveillance methodologies. Encouraging research and investment in cutting-edge technologies ensures the agility to swiftly respond to emerging challenges posed by viral mutations [5].

The global interconnectedness in managing the pandemic underscores the importance of international cooperation. Collaborative efforts in research, data sharing, and capacity-building initiatives are indispensable in fortifying global preparedness against not just SARS-CoV-2 but also future viral threats. The integration of rapid antigen test RNA sequencing into genomic surveillance has broader implications beyond the current pandemic. It sets a precedent for harnessing diagnostic tools for proactive monitoring of infectious diseases, offering a paradigm for early detection and containment. The convergence of diagnostic technologies with genomic surveillance signifies a transformative milestone in pandemic response strategies. It represents the culmination of multidisciplinary efforts, technological innovation, and collaborative endeavors aimed at fortifying our ability to combat infectious diseases. As the world navigates the intricate challenges posed by SARS-CoV-2 and its variants, the synergy between rapid antigen testing and RNA sequencing exemplifies the resilience and adaptability of scientific ingenuity. By leveraging this amalgamation, humanity stands better equipped to navigate the complexities of viral evolution and chart a course toward a safer and healthier future [6].

Conclusion

The adaptability of rapid antigen tests, initially designed for diagnostic purposes, extends beyond their primary function. Leveraging positive test samples for whole virus sequencing and variant detection holds promise in augmenting genomic surveillance efforts. However, addressing technical challenges and standardizing protocols are pivotal for maximizing their utility in preserving comprehensive genomic surveillance amidst the evolving landscape of SARS-CoV-2 variants. In conclusion, the convergence of rapid antigen testing and RNA sequencing signifies a paradigm shift in leveraging diagnostic tools for broader public health objectives, offering a potent strategy to fortify genomic surveillance in the ongoing battle against the COVID-19 pandemic. The integration of positive SARS-CoV-2 rapid antigen test RNA sequencing into genomic surveillance underscores a paradigm shift in pandemic management strategies. While challenges persist, the amalgamation of diagnostic and genomic tools augurs well for comprehensive and dynamic surveillance. In embracing this convergence, stakeholders across the scientific, healthcare, regulatory, and policy domains must collaborate to address technical challenges, optimize methodologies, uphold ethical considerations, and establish standardized protocols. Such concerted efforts are imperative in leveraging the full potential of rapid antigen tests for robust genomic surveillance.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Arshadi, Maniya, Fatemeh Fardsanei, Behnaz Deihim and Zahra Farshadzadeh, et al. "Diagnostic accuracy of rapid antigen tests for COVID-19 detection: A systematic review with meta-analysis." Front Med 9 (2022): 870738.

Google Scholar, Crossref, Indexed at

2. Rai, Praveen, Ballamoole Krishna Kumar, Vijaya Kumar Deekshit and Indrani Karunasagar, et al. "Detection technologies and recent developments in the diagnosis of COVID-19 infection." Appl Microbiol Biotechnol 105 (2021): 441-455.

Google Scholar, Crossref, Indexed at

3. Toft, Casey J., Rebecca A. Bourquin, Alanna E. Sorenson and Paul F. Horwood, et al. "Analytical sensitivity of COVID-19 rapid antigen tests: A case for a robust reference standard." Talanta Open 7 (2023): 100187.

Google Scholar, Crossref, Indexed at

4. Robinson, Matthew L., Agha Mirza, Nicholas Gallagher and Alec Boudreau, et al. "Limitations of molecular and antigen test performance for SARS-CoV-2 in symptomatic and asymptomatic COVID-19 contacts." J Clinic Microbiol 60 (2022): e00187-22.

Google Scholar, Crossref, Indexed at

5. Rector, Annabel, Mandy Bloemen, Gilberte Schiettekatte and Piet Maes, et al. "Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: A gamechanger in genomic surveillance?." Eurosurveillance 28 (2023): 2200618.

Google Scholar, Crossref, Indexed at

6. Raïch-Regué, Dàlia, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt and Marc Noguera-Julian, et al. "Performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests for Omicron and other variants of concern." Front Microbiol 13 (2022): 810576.

Google Scholar, Crossref, Indexed at